A Phase 1 Study of Everolimus Plus Docetaxel Plus Cisplatin as Induction Chemotherapy for Patients With Locally and/or Regionally Advanced Head and Neck Cancer

摘要

BACKGROUNDActivation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in head and neck cancers, and it has been demonstrated that inhibition of mTOR complex 1 sensitizes cell lines to platinum and taxane chemotherapy. The authors conducted a phase 1 study to evaluate the addition of oral everolimus to cisplatin and docetaxel as induction chemotherapy for head and neck cancer.